Mamoun Younes

(Reading, Writing, Speaking)

Eisai/Janssen: Is adenocarcinoma of the esophagus more likely to develop in patients with Barrett's metaplasia with persistent Oxidative DNA Damage?, $166,085, May 1, 2003 to 2006.
American College of Gastroenterology: p53 and DNA ploidy in Barrett’s metaplasia, $21,169, Jul 1, 1997 to Jun 30, 1998.
National Institutes of Health (NIH): p53 and DNA Ploidy in Barrett's Metaplasia, $1,440,770, Jan 9, 2001 to Dec 31, 2005.
The Methodist Hospital Foundation: Clinical significance of the expression of estrogen receptor Beta in breast cancer., $42,000, Jan 1, 1999 to Dec 31, 2000.
The Methodist Hospital Foundation: p53 and DNA ploidy in Barrett’s metaplasia, $97,000, Jan 1, 1995 to Dec 31, 1996.
Janssen Pharmaceutica Inc: Oxidative DNA Damages Index (ODDI) as a surrogate marker for monitoring response of gastroesophageal reflux to treatment with proton pump inhibitors (PPI), $50,000, Feb. 2002 to Feb. 2003.
Eisai/Janssen: Refining the definition of Barrett’s metaplasia, $25,200, Feb 1, 2003 to Jan 31, 2004.
Wendy Will Case Cancer Fund: p53 and DNA ploidy in Barrett’s metaplasia, $24,000, 1998 to 1999.
Astra Pharmaceuticals: Effect of treatment with proton pump inhibitors on oxidative DNA damage and malignant progression in Barrett’s metaplasia, $41,000, 1998 to 2000.
Moran Foundation: Several small projecdts over several years, 1992 to 1999.

• Honma N, Takubo K, Akiyama F, Sawabe M, Arai T, Younes M, Kasumi F, Sakamoto G (Aug 2005) Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast., 47 (2), 195-201
• Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A (Aug 2005) Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death., 130 (4), 501-10
• Granville LA, Younes M, Churg A, Roggli VL, Henderson DW, Cagle PT (Mar 2005) Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma., 13 (1), 75-9
• Younes M, Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor-targeted therapy?, Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 23(4), 923; author reply 92, Feb 2005
• Younes M (Feb 2005) What is the role of cytokeratins in Barrett/cardia differentiation?, 129 (2), 181-2
• El-Zimaity HMT, Wotherspoon A, de Jong D, and the Houston MALT lymphoma Workshop, Interobserver Variation in the Histopathological Assessment of Malt/malt, Blood Cells, Molecules, & Diseases, 34, 6-16, 2005
• Younes M, What Is the Role of Cytokeratins in Barrett's/Cardia Differentiation?, Arch Pathol Lab Med, 129, 181-182, 2005
• Granville L, Younes M, Churg A, Roggli VL, Henderson DW, Cagle PT, Comparison of Monocolonal Versus Polyclonal Calretinin Antibodies for Immunohistochemical Diagnosis of Malignant Mesothelioma, Appl Immunohistochem Mol Morphol, 13, 75-79, 2005
• Honma N, Takubo K, Akiyama F, Sawabe M, Arai T, Younes M, Kasumi F, Sakamoto G, Expression of GCDFP-15 and AR Decrease in Larger or Node-Positive Apocrine Carcinomas of the Breast., Histopathology, 47, 195-201, 2005
• Cammarata PR, Flynn J, Gottipati S, Chu S, Dimitrijevich S, Younes M, Skliris G, Murphy LC., Differential expression and comparative subcellular localization of estrogen receptor beta isoforms in virally-transformed and normal cultured human lens epithelial cells., Exp Eye Res, 81, 165-175, 2005
• Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A., Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death., Br J Haematol, 130, 501-510, 2005
• Younes M., Frozen Section of the Gastrointestinal Tract, Appendix and Peritoneum (Review)., Arch Pathol Lab Med, 129, 1558-1564, 2005
• Younes M., Is the incidence of esophageal adenocarcinomas in patients with Barrett's esophagus (BE) really overestimated? (Letter), Gastroenterology, 129, 2125-2126, 2005
• Henson DE, Dittus C, Younes M, Nguyen H, Albore-Saavedra J, Differential Trends in the Intestinal and Diffuse Types of Gastric Carcinoma in the United States, 1973-2000: Increase in the Signet Ring Cell Type, Arch Pathol Lab Med, 128, 765-770, Jul 2004
• Li R, Younes M, Wheeler TM, Scardino P, Ohori M, Frolov A, Ayala G, Expression of Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) In Human Prostate., The Prostate, 58(2), 193-9, Feb 2004
• Chen X, Lechago J, Ertan A, Ergun G, Verm R, Bridges M, Johnson C, Woods K, Meriano F, Chirala M, Younes M, Expression of the High Mobility Group Proteins HMGI(Y) Correlates With Malignant Progression in Barrett's Metaplasia., Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology., 13(1), 30-3, Jan 2004
• Liu L, Chirala M, Younes M, Expression of Estrogen Receptor-Beta Isoforms in Barrett’s Metaplasia, Dysplasia, and Esophageal Adenocarcinoma, Anticancer Res, 24, 2919-2924, 2004
• Yorke R, Chirala M, Younes M, c-kit proto-oncogene product is rarely detected in colorectal adenocarcinoma, Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 21(20), 3885-6; discussion 3, October 2003
• Yorke R, Younes A, Chirala M, Younes M, Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia, European Journal of Cancer (oxford, England : 1990), 39(14), 2099-102, September 2003
• Honma N, Sakamoto G, Ikenaga M, Kuroiwa K, Younes M, Takubo K, Mucinous cystadenocarcinoma of the breast: a case report and review of the literature, Archives of Pathology & Laboratory Medicine, 127(8), 1031-3, August 2003
• Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, Younes M, Vauthey JN, Carbone A, Younes A, MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival, Blood, 102(3), 1019-27, August 2003
• Li R, Younes M, Frolov A, Wheeler TM, Scardino P, Ohori M, Ayala G, Expression of neutral amino acid transporter ASCT2 in human prostate, Anticancer Research, 23(4), 3413-8, 2003
• Younes M, Ertan A, Lechago J, P53 protein and malignant progression in Barrett's metaplasia (Barrett's esophagus), The American Journal of Gastroenterology, 98(5), 1200-1; author reply, May 2003
• Huttenbach Y, Hamilton C, Lechago J, Younes M, Non-dysplastic and dysplastic Barrett's mucosa and adenocarcinoma lack a subepithelial myofibroblastic cell layer, Anticancer Research, 23(3B), 2261-5, 2003
• Cappelletti V, Veneroni S, Coradini D, Oriana S, Tomasic G, Younes M, Daidone MG, Re: Tamoxifen may be an effective treatment for BRCA1-related breast cancer irrespective of estrogen receptor status, Journal of the National Cancer Institute, 95(8), 629-30, April 2003
• Honma N, Sakamoto G, Akiyama F, Esaki Y, Sawabe M, Arai T, Hosoi T, Harada N, Younes M, Takubo K, Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status, Histopathology, 42(2), 120-7, February 2003
• Chi A, Chen X, Chirala M, Younes M, Differential expression of estrogen receptor beta isoforms in human breast cancer tissue, Anticancer Research, 23(1A), 211-6, 2003
• Liu L, Ergun G, Ertan A, Woods K, Sachs I, Younes M., Detection of oxidative DNA damage in oesophageal biopsies of patients with reflux symptoms and normal pH monitoring, Aliment Pharmacol Ther, 18, 693-698, 2003
• Younes, M., Can proton pump inhibitors be blamed for the rising incidence of esophageal cancer?, Gastroenterology, 125, 1912, 2003
• Daidone MG, Veneroni S, Cappelletti V, Radice P, Pierotti MA, Younes M, Estrogen receptor-beta expression in hereditary breast cancer, Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 20(17), 3752-3; discussion 3, September 2002
• Wei R, Younes M, Immunohistochemical detection of telomerase reverse transcriptase in colorectal adenocarcinoma and benign colonic mucosa, Human Pathology, 33(7), 693-6, July 2002
• Carlson N, Lechago J, Richter J, Sampliner RE, Peterson L, Santella RM, Goldblum JR, Falk GW, Ertan A, Younes M, Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation, The American Journal of Gastroenterology, 97(6), 1340-5, June 2002
• Akgun H, Lechago J, Younes M, Estrogen receptor-beta is expressed in Barrett's metaplasia and associated adenocarcinoma of the esophagus, Anticancer Research, 22(3), 1459-61, 2002
• Witte D, Thomas A, Ali N, Carlson N, Younes M, Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma, Anticancer Research, 22(3), 1463-6, 2002
• Jhala N, Lechago S, Lechago J, Younes M, Is immunostaining for Helicobacter pylori superior to the special stain thiazine in detecting small numbers of H. pylori in gastric biopsies?, Applied Immunohistochemistry & Molecular Morphology : Aimm / Official Publication of the Society for Applied Immunohistochemistry., 10(1), 82-4, March 2002
• Baer S, Casaubon L, Schwartz MR, Marcogliese A, Younes M, Glut3 expression in biopsy specimens of laryngeal carcinoma is associated with poor survival, Laryngoscope, 112(2), 393-6, February 2002
• Clodi K, Asgari Z, Younes M, Palmer JL, Cabanillas F, Carbone A, Andreeff M, Younes A, Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance, Cancer, 94(1), 1-5, January 2002
• Witte D, Ali N, Carlson N, Younes M, Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma, Anticancer Research, 22(5), 2555-2558, 2002
• Younes M, Henson DE, Ertan A, Miller CC, Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type, Scandinavian Journal of Gastroenterology, 37, 1359-1365, 2002
• Fiumara P, Snell V, Li Y, Mukhopadhyay A, Younes M, Gillenwater AM, Cabanillas F, Aggarwal BB, Younes A, Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines, Blood, 98(9), 2784-90, November 2001
• Witte D, Chirala M, Younes A, Li Y, Younes M, Estrogen receptor beta is expressed in human colorectal adenocarcinoma, Human Pathology, 32(9), 940-4, September 2001
• Younes M, Juarez D, Lechago LV, Lerner SP, Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival, Anticancer Research, 21(1B), 575-8, 2001
• Mann S, Laucirica R, Carlson N, Younes PS, Ali N, Younes A, Li Y, Younes M, Estrogen receptor beta expression in invasive breast cancer, Human Pathology, 32(1), 113-8, Jan 2001
• Ertan A, Younes M, Barrett's esophagus, Digestive Diseases and Sciences, 45(8), 1670-3, August 2000
• Younes M, Lechago J, Ertan A, Finnie D, Younes A, Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus, Human Pathology, 31(4), 434-8, April 2000
• Korin HW, Schwartz MR, Chirala M, Younes M, Optimized cyclin D1 immunoperoxidase staining in mantle cell lymphoma, 8(1), 57-60, March 2000
• Younes M, Schwartz MR, Ertan A, Finnie D, Younes A, Fas ligand expression in esophageal carcinomas and their lymph node metastases, Cancer, 88(3), 524-8, February 2000
• Younes M, Lechago J, Chakraborty S, Ostrowski M, Bridges M, Meriano F, Solcher D, Barroso A, Whitman D, Schwartz J, Johnson C, Schmulen AC, Verm R, Balsaver A, Carlson N, Ertant A, Relationship between dysplasia, p53 protein accumulation, DNA ploidy, and Glut1 overexpression in Barrett metaplasia, Scandinavian Journal of Gastroenterology, 35(2), 131-7, February 2000
• Younes M, Schwartz MR, Finnie D, Younes A, Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus, Human Pathology, 30(11), 1309-13, November 1999
• Mumford JL, Tian D, Younes M, Hu F, Lan Q, Ostrowski ML, He X, Feng Z, Detection of p53 protein accumulation in sputum and lung adenocarcinoma associated with indoor exposure to unvented coal smoke in China, Anticancer Research, 19(2A), 951-8, 1999
• Younes M, Schwartz MR, Finnie D, Younes A., Overexpression of Fas Ligand (FasL) during malignant transformation in the large bowel and in Barrett’s metaplasia of the esophagus, Human Pathology, 1309-1313, 1999
• Truong L D, Williams R, Ngo T, Cawood C, Chevez-Barrios P, Awalt H L, Brown R W, Younes M, Ro J Y, Adult mesoblastic nephroma: expansion of the morphologic spectrum and review of literature, American Journal of Surgical Pathology, 22(7), 827-39, July 1998
• Baer S C, Casaubon L, Younes M, Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia, Journal of The American Academy of Dermatology, 37(4), 575-7, October 1997
• Younes M, Brown R W, Stephenson M, Gondo M, Cagle P T, Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival, Cancer, 80(6), 1046-51, 15 Sep 1997
• Anton R C, Brown R W, Younes M, Gondo M M, Stephenson M A, Cagle P T, Absence of prognostic significance of bcl-2 immunopositivity in non-small cell lung cancer: analysis of 427 cases, Human Pathology, 28(9), 1079-82, September 1997
• Younes M, Lechago L V, Somoano J R, Mosharaf M, Lechago J, Immunohistochemical detection of Glut3 in human tumors and normal tissues, Anticancer Research, 17(4A), 2747-50, July 1997
• Younes M, Ertan A, Lechago L V, Somoano J, Lechago J, Human erythrocyte glucose transporter (Glut1) is immunohistochemically detected as a late event during malignant progression in Barrett's metaplasia, Cancer Epidemiology, Biomarkers and Prevention, 6(5), 303-5, May 1997
• Younes M, Ertan A, Lechago L V, Somoano J R, Lechago J, p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia, Digestive Diseases and Sciences, 42(4), 697-701, April 1997
• Younes M, Laucirica R, Lack of prognostic significance of histological grade in node-negative invasive breast carcinoma, Clinical Cancer Research, 3(4), 601-4, April 1997
• Younes M, Lane M, Miller C C, Laucirica R, Stratified multivariate analysis of prognostic markers in breast cancer: a preliminary report, Anticancer Research, 17(2B), 1383-90, March 1997
• Yi E S, Harclerode D, Gondo M, Stephenson M, Brown R W, Younes M, Cagle P T, High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas, Modern Pathology, 10(2), 142-8, February 1997
• Younes M, Ertan A, Lechago LV, Somoano JR, Lechago JL, p53 protein accumulation is a specific marker of malignant potential in Barrett's metaplasia, Digestive Diseases and Sciences, 42, 697-701, 1997
• Younes M, Lane M, Miller CC, Laucirica R, Stratified multivariate analysis of prognostic markers in breast cancer: A preliminary report, Anticancer Research, 17, 1383-1390, 1997
• Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J, Immunohistochemical detection of Glut 3 in human tumors and normal tissues, Anticancer Research, 17, 2747-2750, 1997
• Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT, Overexpression of Glut1 and Glut3 in stage I non-small cell lung carcinoma is associated with worse survival, Cancer, 89, 1046-1051, 1997
• Clodi K, Younes A, Goodacre A, Roberts M, Palmer J, Younes M, Cabanillas F, Andreeff M., Analysis of p53 gene deletions in patients with non-Hodgkin’s lymphoma by dual color fluorescence in-situ hybridization, British Journal of Haematology, 98, 913-921, 1997
• Younes M, Fernandez L, Lechago J, Transforming growth factor alpha (TGF-alpha) expression in biopsies of colorectal carcinoma is a significant prognostic indicator, Anticancer Research, 16(4A), 1999-2003, July 1996
• Younes M, Lechago LV, Lechago J, Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases, Clinical Cancer Research, 2(7), 1151-4, July 1996
• Younes M, Lechago L V, Somoano J R, Mosharaf M, Lechago J, Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers, Cancer Research, 56(5), 1164-7, 1 Mar 1996
• Younes M, Fernandez L, Laucirica R., Transforming growth factor-ß type II receptor (TGFß-RII) is infrequently expressed in human breast cancer, The Breast Journal, 2, 150-153, 1996
• Younes M, Laucirica R, Miller CC, Brown R., The prognostic value of estrogen receptor immunocytochemistry (ERICA) in breast cancer does not depend on the immunostaining intensity, Breast Disease, 9, 157-170, 1996
• Younes M, Mody D, Miller CC, Lechago LV, Laucirica R., Estimating the proliferative activity in breast cancer: is Ki-67 immunostaining necessary?, Breast Disease, 9, 269-275, 1996
• Ertan A, Zimmerman M, Younes M, Esophageal adenocarcinoma associated with Barrett's esophagus: long-term management with laser ablation, American Journal of Gastroenterology, 90(12), 2201-3, December 1995
• Younes M, Brown R W, Mody D R, Fernandez L, Laucirica R, GLUT1 expression in human breast carcinoma: correlation with known prognostic markers, Anticancer Research, 15(6B), 2895-8, November 1995
• Younes M, Riley S, Genta R M, Mosharaf M, Mody D R, p53 protein accumulation in tumors of the ampulla of Vater, Cancer, 76(7), 1150-4, 1 Oct 1995
• Younes M, Lebovitz R M, Bommer K E, Cagle P T, Morton D, Khan S, Laucirica R, p53 accumulation in benign breast biopsy specimens, Human Pathology, 26, 155-8, February 1995
• Younes M, Katikaneni P R, Lechago J., Association between mucosal hyperplasia of the appendix and adenocarcinoma of the colon, Histopathology, 26, 33-7, January 1995
• Younes M, Katikaneni P R, Lechago L V, Lechago J, HAM56 antibody: a tool in the differential diagnosis between colorectal and gynecological malignancy, Modern Pathology, 7(3), 396-400, April 1994
• Younes M, Paus R, Stenn K S, Braverman I, Keh-Yen A, Localization and abundance of fodrin during keratinocyte differentiation [letter], In Vitro Cellular and Developmental biology. Animal, 30A(2), 69-74, February 1994
• Younes M, Katikaneni P R, Lechago J, The value of the preoperative mucosal biopsy in the diagnosis of colorectal mucinous adenocarcinoma, Cancer, 72(12), 3588-92, 15 Dec 1993
• Younes M, Lebovitz R M, Lechago L V, Lechago J, p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study, Gastroenterology, 105(6), 1637-42, December 1993
• Younes M, Podesta A, Helie M, Buckley P, Infection of T but not B lymphocytes by cytomegalovirus in lymph node. An immunophenotypic study, American Journal of Surgical Pathology, 15(1), 75-80, January 1991
• Younes M, Sussman J, True L D, The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder, Cancer, 66, 543-8, 01 Aug 1990
• Younes M, Harris A S, Morrow J S, Fodrin as a differentiation marker. Redistributions in colonic neoplasia, American Journal of Pathology, 135(6), 1197-212, December 1989
• Younes M, Wank SA, Vinayek R, Jensen RT, Gardner JD., Regulation of bombesin receptors on pancreatic acini by colecystokinin, American Journal of Physiology, 56, G291-G298, 1989
• Younes M, Jensen RT, Gardner JD., Cholecystokinin–induced residual stimulation of enzyme secretion from mouse pancreatic acini, Biochemica et Biophysica Acta, 930, 410-418, 1987